SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Operating Cash Flow
Cash generated by the company's core business operations during the period.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Operating Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Operating cash flow declines year over year
Q3 FY2026 operating cash flow of $5.94M (cash outflow) fell 16.0% year over year, behind the -10.9% change in trailing-twelve-month operating cash flow. Sequentially, it fell 21.7% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -16.0% toward the trailing-twelve-month pace of -10.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (28.39M) USD
- Year-over-year change
- +19.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.39M) | +19.8% |
| FY2024 | 2024-12-31 | (35.4M) | -12.7% |
| FY2023 | 2023-12-31 | (31.41M) | -31.9% |
| FY2022 | 2022-12-31 | (23.81M) | +8.5% |
| FY2021 | 2021-12-31 | (26.02M) | — |
Operating Cash Flow vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.9% is the 8th highest of 11, against a peer median of +15.6%.
- Over three fiscal years its annual growth of +6.0% compares with a peer median of +14.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.98B USD | +97.4% | +13.4% | 34.0% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥1.17B CNY | +954.4% | +21.5% | 210.2% |
| LTM Aug 2026 | $379.31M USD | +264.6% | +16.0% | 54.0% | |
| LTM Sep 2026 | $229.03M USD | +23.8% | +88.1% | — | |
| LTM Mar 2026 | $134.47M USD | +12.4% | +54.4% | — | |
| LTM Mar 2026 | $95.35M USD | +18.7% | -2.3% | 273.5% | |
| LTM Mar 2026 | $85.93M USD | -67.5% | -6.6% | 38.1% | |
| LTM Mar 2026 | $75.36M USD | -4529.6% | +15.5% | 634.2% | |
| LTM Mar 2026 | $69.96M USD | +0.5% | -2.3% | 44.5% | |
| LTM Mar 2026 | $43.76M USD | -58.5% | -12.4% | 261.7% | |
| LTM Sep 2026 | $27.3M USD | -10.9% | +6.0% | — | |
| Peer median (excluding SLS) | — | +15.6% | +14.4% | 132.1% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| Deferred Income Tax | (239K) | (457K) | 0 | 0 | 0 |
| Stock-Based Compensation | 1.01M | 1.73M | 1.39M | 1.56M | 1.96M |
| Change in Working Capital | (7.62M) | 5.64M | 3.35M | (6.65M) | (4.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.51M) | 1.21M | 2.3M | (2.14M) | (535K) |
| Other Working Capital | (5.1M) | 4.43M | 1.04M | (4.51M) | (3.54M) |
| Other Non-Cash Items | 248K | 10.13M | (36.67M) | (30.95M) | 597K |
| Operating Cash Flow | (26.02M) | (23.81M) | (31.41M) | (35.4M) | (28.39M) |
| Capital Expenditures | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (4.5M) | (5.5M) | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.01M | 23.99M | 22.23M | 46.16M | 86.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.07M | 85K | 90K | 594K | (527K) |
| Financing Cash Flow | 12.07M | 24.08M | 22.32M | 46.76M | 86.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.95M) | (4.23M) | (14.6M) | 11.36M | 57.91M |
| Free Cash Flow | (26.02M) | (28.31M) | (36.91M) | (35.4M) | (28.39M) |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.